Viewing Study NCT05067127

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 5:08 AM
Ignite Modification Date: 2025-12-26 @ 4:12 AM
Study NCT ID: NCT05067127
Status: COMPLETED
Last Update Posted: 2025-08-06
First Post: 2021-09-23
Is NOT Gene Therapy: False
Has Adverse Events: True
Brief Title: Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Sponsor: Apellis Pharmaceuticals, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None C3G View
None IC-MPGN View
None C3 Glomerulopathy View
None C3 Glomerulonephritis View
None Complement 3 Glomerulopathy View
None Complement 3 Glomerulopathy (C3G) View
None Complement 3 Glomerulonephritis View
None Dense Deposit Disease View
None DDD View
None Membranoproliferative Glomerulonephritis View
None Membranoproliferative Glomerulonephritis (MPGN) View
None Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) View
Keywords: